The estimated Net Worth of Melvin Md Sharoky is at least 3.44 百万$ dollars as of 15 May 2023. Melvin Sharoky owns over 20,000 units of Insmed Inc stock worth over 727,600$ and over the last 22 years he sold INSM stock worth over 2,452,420$. In addition, he makes 262,500$ as Independent Director at Insmed Inc.
Sign up
Melvin Sharoky INSM stock SEC Form 4 insiders trading
Melvin has made over 15 trades of the Insmed Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of INSM stock worth 385,800$ on 15 May 2023.
The largest trade he's ever made was buying 88,889 units of Insmed Inc stock on 13 August 2014 worth over 1,000,001$. On average, Melvin trades about 8,612 units every 127 days since 2003. As of 15 May 2023 he still owns at least 10,000 units of Insmed Inc stock.
You can see the complete history of Melvin Sharoky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Melvin Sharoky biography
Dr. Melvin A. Sharoky M.D. serves as Independent Director of the Company. From 2007 to 2012, He is Member of Nominations and Governance Committee. he was a member of the board of directors of Par Pharmaceutical Companies, Inc. (NYSE:PRX), a publicly-traded pharmaceutical manufacturer. From 2002 to 2007, Dr. Sharoky was President and Chief Executive Officer of Somerset Pharmaceuticals, Inc. Dr. Sharoky continued as a consultant to Somerset until 2007. From 2001 to 2002, Dr. Sharoky was retired. From July 1995 to June 2001, Dr. Sharoky served as President of Somerset Pharmaceuticals. From 1995 through 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc. (now Actavis plc), and from 1993 to 1998 he was President and Chief Executive Officer of Watson’s wholly-owned subsidiary, Circa Pharmaceuticals, Inc. From 1988 to 1993, Dr. Sharoky held various senior executive positions with Circa Pharmaceuticals. From February 1986 to June 1988, Dr. Sharoky was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. Dr. Sharoky holds a Bachelor of Arts degree in biology from the University of Maryland in Baltimore County and a Doctor of Medicine degree from the University of Maryland School of Medicine. Dr. Sharoky has more than 30 years of experience in the pharmaceutical industry. The Board believes that, in addition to his medical experience as a physician, Dr. Sharoky's background as an executive of pharmaceutical companies, as well as his public company board service, brings valuable senior management, leadership, financial and strategic planning experience to our Board.
What is the salary of Melvin Sharoky?
As the Independent Director of Insmed Inc, the total compensation of Melvin Sharoky at Insmed Inc is 262,500$. There are 15 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of 7,175,090$.
How old is Melvin Sharoky?
Melvin Sharoky is 69, he's been the Independent Director of Insmed Inc since 2010. There are 1 older and 22 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
What's Melvin Sharoky's mailing address?
Melvin's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.
Insiders trading at Insmed Inc
Over the last 22 years, insiders at Insmed Inc have traded over 46,121,705$ worth of Insmed Inc stock and bought 1,080,212 units worth 8,226,993$ . The most active insiders traders include Llc Fmr、William Lewis、Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of 2,452,158$. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth 407,689$.
What does Insmed Inc do?
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
What does Insmed Inc's logo look like?
Complete history of Melvin Sharoky stock trades at Insmed Inc
Insmed Inc executives and stock owners
Insmed Inc executives and other stock owners filed with the SEC include:
-
William Lewis,
Chairman of the Board, President, Chief Executive Officer -
Roger Adsett,
Chief Operating Officer -
Christine Pellizzari,
Chief Legal Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
William H. Lewis J.D., M.B.A.,
Pres, CEO & Chairman -
Dr. Martina Flammer M.B.A., M.D.,
Chief Medical Officer -
John Goll,
Chief Accounting Officer -
Roger Adsett,
Chief Operating Officer -
Christine A. Pellizzari J.D.,
Consultant -
Sara M. Bonstein MBA,
Chief Financial Officer -
John Goll III,
Sr. VP & Chief Accounting Officer -
David Brennan,
Lead Independent Director -
Alfred Altomari,
Independent Director -
Steinar Engelsen,
Independent Director -
David McGirr,
Independent Director -
Melvin Sharoky,
Independent Director -
Leo Lee,
Independent Director -
Elizabeth Anderson,
Independent Director -
Clarissa Desjardins,
Independent Director -
Carol Schafer,
Director -
Martina Flammer,
Chief Medical Officer -
John Soriano,
Chief Compliance Officer -
Sara Bonstein,
Chief Financial Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
Mandy Fahey,
Sr. Director of Corp. Communications -
Michael Alexander Smith,
Sr. VP & Gen. Counsel -
John D. Soriano J.D.,
Chief Compliance Officer -
Eleanor Barisser,
Associate Director of Investor Relations -
Paolo Tombesi,
Chief Financial Officer -
Paul Streck,
Chief Medical Officer -
Eugene Jeffrey Sullivan,
Chief Medical Officer -
Myrtle S Potter,
Director -
Donald J Jr Hayden,
Director -
Geoffrey Allan,
President, CEO and Chairman -
Stephen C. Glover,
President Follow-on Biologics -
Doug Farrar,
Vice President, ITP -
Michael Duncan,
Principal Financial Officer -
Thomas A Keuer,
VP, ITP (Subsidiary) -
Philip J Young,
Chief Business Officer and EVP -
Ronald D Gunn,
Executive Vice President -
Mark Quigley,
Vice President, Quality -
Randall W Whitcomb,
Director -
Peggy Berry,
Vice President, Regulatory -
Renu Gupta,
Chief Medical Officer -
Richard S Kollender,
Director -
Matthew Pauls,
Chief Commercial Officer -
Llc Fmr,
10% owner -
Andrea Holtzman Drucker,
Senior V.P., General Counsel -
Nicholas A. Jr. La Bella,
Chief Scientific Officer -
Kenneth G Condon,
Director -
Kevin P Tully,
Executive VP & CFO -
Timothy Whitten,
President & CEO -
Graham K Crooke,
Director -
Nicholas Lee Gurreri,
Senior VP, Commercial Ops -
Dennis M Lanfear,
Director -
John Drayton Wise,
Chief Commercial Officer -
Michael Alexander Smith,
Chief Legal Officer